OBJECTIVES: To develop a core outcome set (COS) for use in effectiveness trials of interventions aiming to improve the appropriateness of polypharmacy in older people in primary care. DESIGN: Standard COS development methodology was followed, comprising identification of outcomes of studies from an update of a Cochrane systematic review and previously collected qualitative data and an online Delphi consensus exercise involving three rounds. PARTICIPANTS: An international panel of 160 stakeholders comprising 120 healthcare experts and a public participant panel of 40 older people. MEASUREMENTS: Outcomes identified from studies included in the Cochrane review and secondary analysis of previously collected qualitative data were scored on a 9-point Likert scale using the GRADE scoring system anchored at 1 (not important) and 9 (critical). Consensus criteria for the COS were defined as 70% or more of participants scoring the outcome as critical and 15% or fewer scoring the outcome as not important. RESULTS: Twenty-nine outcomes identified from the Cochrane review and existing qualitative data were included in the Delphi exercise. The final COS comprised 16 outcomes. The 7 highest-ranked outcomes were serious adverse drug reactions, medication appropriateness, falls, medication regimen complexity, quality of life, mortality, and medication side effects. CONCLUSION: A COS for interventions aiming to improve the appropriateness of polypharmacy for older people in primary care has been developed. Future work will focus on identifying appropriate tools to measure these outcomes and testing the implementation of the COS. J Am Geriatr Soc 0:1-7, 2018.
G lobally, the number of older people (≥65) is growing and is predicted to reach nearly 1.5 billion by 2050, representing almost 25% of the population in the United Kingdom (UK) and 15% in the United States.
1,2 The use of multiple medicines (polypharmacy) in older adults is commonplace. 3 Obtaining a balance between the prescribing of too many medicines (inappropriate polypharmacy) and many medicines (appropriate polypharmacy) is challenging, particularly when prescribing for older people with multimorbidity. 4, 5 Polypharmacy is associated with greater risk of potentially inappropriate prescribing, whereby the negative effects associated with medication prescribing outweigh the potential benefits. 6 Studies to improve the appropriateness of polypharmacy in older people often differ in the outcomes reported, resulting in an inability to form conclusions about intervention effectiveness for specific outcomes (e.g. hospitalizations). 7 The Core Outcome Measures for Effectiveness Trials (COMET) initiative has proposed the development and reporting of a core outcome set (COS) as one method of addressing this problem. 8, 9 A COS is an agreed-upon standardized set of outcomes that should be measured and reported as a minimum in all trials in a specific clinical area. 8 The aim of this study was to develop a COS for use in trials investigating the effectiveness of interventions aimed at improving the appropriateness of polypharmacy in older people in primary care.
METHODS
Development of the COS followed the COMET initiative methodology 8 and has been reported according to the Core Outcome Set-STAndards for Reporting (COS-STAR) guidelines. 10 The study involved two phases: generating and refining a long-list of outcomes and a Delphi consensus exercise. A project steering group (PSG) comprising staff members (academic general practitioners, pharmacists, research staff) from Queen's University Belfast and the Royal College of Surgeons in Ireland oversaw the COS development process. This phase involved three steps: identifying outcomes used in previous studies by updating a Cochrane systematic review, 7 identifying outcomes from previously collected qualitative data, 11, 12 and initial screening of outcomes from steps 1 and 2.
Identification of Outcomes Used in Previous Intervention Studies
Outcomes were extracted from 20 studies included in an ongoing update of a Cochrane review. 7 Studies were included if they aimed to improve the appropriateness of polypharmacy in older people in any healthcare setting (e.g., hospital, community, nursing homes) and included a validated measure of potentially inappropriate prescribing (e.g., Beers Criteria
13
).
Secondary Analysis of Qualitative Data
Secondary analysis was conducted on an existing qualitative dataset involving semistructured interviews (15 general practitioners, 15 community pharmacists) and focus groups (50 older adults receiving polypharmacy). 11, 12 Data were extracted on outcomes deemed of importance to participants for future polypharmacy-focused intervention.
Initial Screening of the Long List of Outcomes
The PSG reviewed the outcomes identified in Steps 1 and 2 to produce a long list of outcomes for the Delphi consensus exercise (Phase 2). Refinement involved identifying any process measures (outcomes related to intervention implementation), duplicate outcomes, and outcomes outside the scope of the COS (irrelevant to the specific interventions and study population). The PSG then categorized outcomes into 8 themes: medication-related outcomes, healthcare utilisation, patient-related outcomes, satisfaction, adverse effects or harms, clinical outcomes, knowledge and resource use. Phase 2 involved a Delphi consensus exercise with key stakeholders to reach consensus on the outcomes to include in the COS; 8 identification of panel members, development of the Delphi questionnaire, and the main consensus exercise.
Identification of Panel Members
There are no formal guidelines as to how many participants should form a Delphi panel for COS development; 8, 14 previous studies have included between 10 and 300 participants.
14 To ensure elicitation of a range of opinions, a target of 160 participants (40 public participants, 120 international experts) were recruited. Selection of expert panel members involved discussions among the PSG and compilation of lists of experts with knowledge relevant to the scope of the COS (Table S1 ). Individuals were selected if they were researchers or clinicians with expertise relating to the care of or prescribing for older people (based on the PSG's knowledge of their research profiles and publication records), were editors of key journals in geriatric medicine, or represented the interests of older people (involved with support groups or charities). Selection of the public participant panel was facilitated through publicity (e.g., newsletters, social media) at charities and organizations in Northern Ireland. Communitydwelling individuals aged 65 and older were eligible for inclusion. Potential participants were e-mailed invitations, which included participant information sheets and consent forms, which were signed and returned. Experts were also asked to suggest colleagues who could be included as Delphi panel members. Recruitment was conducted in staggered batches until the required sample size was achieved.
Development of Delphi Questionnaire
Outcomes identified in Phase 1 were listed alphabetically in the questionnaire under each outcome theme to avoid potential weighting effects. Detailed instructions on questionnaire completion were included, with a plain-English definition of each outcome. Participants were asked to rate each outcome on how important it was to measure in studies aimed at improving the appropriateness of polypharmacy on a 9-point Likert scale anchored at 1 (limited importance) and 9 (critical importance), based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) scoring system, 15 as recommended in COMET. 10 There were 3 scoring categories (1-3, limited importance; 4-6, important but not critical; 7-9, critical). An "unable to score" option was included for those unsure how to rate an outcome. At the end of Round 1, participants were asked to suggest additional outcomes for inclusion in the COS. The questionnaire was piloted with a convenience sample (n = 5) of researchers based at the School of Pharmacy, Queen's University Belfast to check for face and content validity. Responses from the pilot questionnaire were positive, so no changes were deemed necessary.
Delphi Consensus Exercise
The consensus exercise encompassed 3 rounds of Delphi questionnaires, as recommended in the COMET initiative, 8 distributed using a web-based survey tool ( Figure S1 ). All consenting participants were e-mailed a web link to access the questionnaire. Only respondents who completed a round were invited to complete the next round. Round 2 consisted of all outcomes from Round 1 plus additional outcomes that the Delphi panel suggested. Round 3 consisted of outcomes for which no consensus had been reached in the second round. In Rounds 2 and 3, participants were e-mailed their individual scores, together with group feedback (number of participants scoring within each GRADE category) ( Figure S1 ) and asked to reconsider their own scores in light of the group response when scoring outcomes in Rounds 2 and 3.
Data Analysis
All statistical analysis was performed using SPSS version 22.0 (IBM Corp., Armonk, NY). Consensus criteria were specified a priori; any outcome with a rating of 7 to 9 by 70% or more of the panel and 1 to 3 by 15% or fewer was to be included in the COS, and any outcome with a rating of 1 to 3 by 70% or more of the panel and 7 to 9 by 15% or fewer was to be excluded. 8 All other combinations indicated that no consensus had been achieved for the outcome. A higher threshold of 75% or more of the panel rating 7 to 9 and 25% or fewer rating 1 to 3 was applied if a higher proportion of outcomes than expected were rated critical (based on the PSG's judgement and giving due consideration to current COMET and Cochrane Collaboration recommendations regarding outcomes). 7, 16 Round 1 responses were analyzed according to the number of participants scoring each outcome within the GRADE criteria (1-3, 4-6, 7-9) for the purpose of group feedback in Round 2. Responses from Round 2 were analyzed using the same consensus criteria as in Round 1. Items for which consensus was not achieved were carried forward to Round 3, during which responses were analyzed using the more stringent criteria. The PSG then further categorized the final COS into overarching outcome themes of healthrelated areas (e.g., knowledge). 17 The 7 highest-ranking outcomes (from those included in the final COS from Rounds 2 and 3) were also determined based on the percentage of individuals scoring an outcome as critical (7) (8) (9) . The rationale behind this deviation from the protocol was that the median number of outcomes reported within Cochrane reviews was 7. 16 The completed COS-STAR checklist is included in Table S2 . 10 
RESULTS
In Phase 1, review of all data sources identified 54 potential outcomes: 32 outcomes from the Cochrane review 7 and 22 from the qualitative data. 11, 12 Initial screening of these outcomes by the PSG resulted in a final long list of 29 outcomes (Figure 1) .
In Phase 2, 152 (41 public, 111 expert) of 163 invited participants (93.3%) completed Round 1 ( Table 1,  Table S3 ). Demographic details of the Delphi panel members are provided in Table 1 . The expert panel consisted of pharmacists, researchers, and doctors residing in Australia, North America, and Europe, with the majority of participants located in the United Kingdom (40.5%), Ireland (9.0%), Canada (8.1%), and Spain (8.1%). An additional 29 outcomes were suggested; after review by the PSG, most were considered to overlap with existing outcomes or to be outside the scope of the COS (Table S4) . Four new outcomes were included in Round 2 of the Delphi questionnaire (medication regimen complexity, patient perception of treatment (or medication) burden, caregiver burden and carers satisfaction with the prescribing of many medicines (polypharmacy)), resulting in 33 outcomes going forward into Round 2.
One hundred forty (38 public, 102 expert) of 152 participants (92.1%) completed Round 2 questionnaires. Analysis of Round 2 data (using the a priori consensus criteria) resulted in 12 outcomes being included in the final COS and the remaining 21 outcomes for which consensus was not reached going forward into Round 3 (Table S5) . One hundred twenty-seven (35 public, 92 expert) of 140 participants (90.7%) completed Round 3 questionnaires. Application of the more stringent consensus criteria resulted in four additional outcomes being included in the final COS; the remaining 17 outcomes were excluded (Table S6) , resulting in a final COS consisting of 16 outcomes across 6 overarching themes ( Table 2 ). The 7 highest-ranking outcomes were serious adverse drug reactions, medication appropriateness, falls, medication regimen complexity, quality of life, mortality, and medication side effects. There were some differences in scoring between the public and expert panels. For example, in Round 3, the public participants but not the expert panel scored the outcomes pain and patient satisfaction with care provided highly (reached the a priori consensus criteria for inclusion in the COS) (Tables 4-6 ).
DISCUSSION
This study followed formal methodological guidance, involving key stakeholders to develop a COS for use in effectiveness studies aiming to improve the appropriateness of polypharmacy in older people in primary care. 8 The 16 outcomes identified, with priority given to the 7 highest-ranking outcomes, can be used in future studies within the scope of the COS. The adoption of this COS will streamline outcomes routinely measured in trials investigating the appropriateness of polypharmacy in older people in primary care.
Polypharmacy management in older adults is an active area of research, with numerous calls for trials to consider the relevance of outcomes selected to assess interventions targeting the appropriateness of polypharmacy in older people. 18, 19 Alongside the development of the current COS for use in polypharmacy interventions, a number of other COSs are being developed in the area of pharmaceutical care (e.g., optimization of prescribing for older adults in The number of 'regular' medicines prescribed
The total number of 'regular' medications that a patient has been prescribed (i.e. a prescribed medication that is scheduled or part of a repeat prescription), which would not include over-the-counter and herbal products if used regularly) Indicates where closely related outcomes were grouped together, with the main outcome underlined.
nursing homes, 20 medication reviews in older people in any healthcare setting 21 ). Each COS has a unique scope, but collectively, their implementation will add rigor to effectiveness studies of pharmaceutical care. This will ultimately facilitate comparison and synthesis of outcome data across studies, helping to determine which interventions work and inform clinical decision-making and health policy. 22 This study has several strengths. First, we followed COS development guidelines, as outlined in the COMET initiative, 8 as well as the COS-STAR guidelines, 10 which detail the items that COS developers should report (Table S2) . Second, during Phase 1, the identification of outcomes was not restricted to the results from the Cochrane review. Outcomes were extracted from existing qualitative data (involving general practitioners, pharmacists, patients), which elicited views on potential outcomes, 11, 12 resulting in the opinions of a broad range of stakeholders being included in the development process. 23, 24 Third, the Delphi panel convened for this study included experts with a diverse range of nationalities and public participants. In line with the scope of this COS, it was important to involve older people to facilitate a move away from outcomes selected only by researchers. 25 The value of public participants' involvement was evidenced within the final round of the consensus exercise, because the outcome patient knowledge would not have been included in the final COS if only experts had been included. Finally, a high response rate across the 3 Delphi rounds (93.3%, 92.1%, and 90.7%, respectively) was achieved and is similar to that reported in other COSs. 20 Some limitations must be noted. First, participants in the Delphi panel were confined to English speakers, and public participants were sampled only from Northern Ireland, although it is unclear whether including panel members outside of this location would have resulted in different outcomes being selected for inclusion in the COS. Second, for financial reasons, we were unable to supplement the Delphi rounds with a face-to-face consensus meeting, with other COS studies not conducting meetings for similar reasons. 20, 21 Finally, the number of outcomes included in the COS could be considered large, but this may be related to the scope of the COS, because a wide range of multifaceted approaches to interventions (provided to improve the appropriateness of polypharmacy), 7 may affect resource use, medications, and the patient.
We have endeavored to generate a concise set of outcomes that would be useful to researchers by implementing more stringent consensus criteria (≥75% scoring 7-9) in Round 3. Furthermore, we recognize that having many outcomes may be impractical and highlight the 7 highestranking outcomes (in line with current COMET and Cochrane Collaboration recommendations), 7, 16 suggesting that these should be priority outcomes, with the remaining outcomes included depending on the specific interventions or underlying theoretical frameworks.
This work has identified which outcomes should be considered for inclusion in trials focusing on improving the appropriateness of polypharmacy in older people in primary care. The next crucial step will be to determine how these outcomes should be measured. For example, within the updated Cochrane review, three different measurement tools were used (15D 29 will be used to inform selection of the most appropriate instrument when more than one instrument is available. In cases in which there is no appropriate tool for use in older people, existing tools may need to be adapted and validated in this population, or new tools may be need to be developed.
CONCLUSION
This work has identified a list of 16 outcomes that should be considered for inclusion in effectiveness studies aimed at improving the appropriateness of polypharmacy in older people in primary care. The implementation of this COS may benefit older people and healthcare providers by enabling evaluation of current practice and facilitating evidence synthesis across studies. Future work should determine the most appropriate way to measure each outcome included in this COS.
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